CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Fesoterodine fumarate

Last Updated: April 27, 2012
Result type: Reports
Project Number: SR0277-000
Product Line: Reimbursement Review

Generic Name: Fesoterodine fumarate

Brand Name: Toviaz

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Overactive bladder

Indications: Bladder, overactive

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 18, 2012

Recommendation Type: List in a similar manner